CHAM BE RLAIN
U NIVE RS ITY
W EEK 4 M IDT ERM EXA M INAT ION
NR-546 Advanced Pharmacology:
Psychopharmacology for the
PMHNP
Course: NR-546 Advanced Pharmacology
Total Questions: 75 Multiple Choice
Academic Year:
Curriculum: Weeks 1 - 4 Comprehensive
100% C or r ect Answer s | Gr ad e A Ver ified
,NR-546 Midterm Exam | Advanced Pharmacology Psychopharmacology for the PMHNP Chamberlain University | 2026-2027
Section 1: Neurobiology and Neurotransmission Fundamentals
(Weeks 1-2)
Q1: A PMHNP student is reviewing synaptic neurotransmission. Which of the following correctly describes
the sequence of events at a chemical synapse?
A. Action potential arrives at the axon terminal, calcium enters the presynaptic terminal,
synaptic vesicles fuse with the presynaptic membrane, neurotransmitter is released into the
synaptic cleft, and binds to postsynaptic receptors [CORRECT]
B. Neurotransmitter is synthesized in the postsynaptic neuron, travels across the synaptic cleft, binds to
presynaptic autoreceptors, and triggers calcium release from intracellular stores
C. Calcium is released from the postsynaptic neuron, vesicles migrate from the postsynaptic
membrane, neurotransmitter diffuses across the cleft, and binds to presynaptic receptors
D. The action potential directly causes neurotransmitter release without calcium involvement, the
neurotransmitter binds to ion channels, and the signal is terminated by enzymatic degradation only
Correct Answer: A
Rationale: The correct sequence of synaptic transmission begins with the arrival of an action potential at the axon
terminal, which opens voltage-gated calcium channels, allowing calcium to enter the presynaptic terminal. This calcium
influx triggers synaptic vesicles containing neurotransmitter to fuse with the presynaptic membrane and release their
contents into the synaptic cleft. The neurotransmitter then diffuses across the cleft and binds to specific receptors on the
postsynaptic membrane. Option B incorrectly describes neurotransmitter synthesis in the postsynaptic neuron and
presynaptic autoreceptor binding as the primary event. Option C reverses the presynaptic and postsynaptic roles. Option D
is incorrect because calcium influx is essential for vesicle fusion and neurotransmitter release, and signal termination
involves reuptake, enzymatic degradation, and diffusion, not degradation alone.
Q2: A patient with major depressive disorder (MDD) is prescribed an SSRI. The PMHNP explains that the
therapeutic effect requires downregulation of which receptor type?
A. 5-HT2A receptors
B. 5-HT1A autoreceptors [CORRECT]
C. 5-HT3 receptors
D. 5-HT2C receptors
Correct Answer: B
Rationale: SSRIs initially block the serotonin transporter (SERT), increasing serotonin in the synaptic cleft. However, the
acute increase in synaptic serotonin also activates presynaptic 5-HT1A autoreceptors, which provide negative feedback and
reduce further serotonin release. Over 2-4 weeks of treatment, these 5-HT1A autoreceptors become desensitized and
downregulated, removing the inhibitory feedback and allowing sustained enhancement of serotonergic neurotransmission.
This delay in autoreceptor downregulation explains the therapeutic lag observed with SSRIs. 5-HT2A receptors are targeted
by antipsychotics and are associated with hallucinogenic effects. 5-HT3 receptors are involved in nausea and are targeted
by antiemetics such as ondansetron. 5-HT2C receptors are primarily associated with appetite regulation.
Q3: Which brain region is the primary source of norepinephrine (NE) and is most relevant to understanding
the pathophysiology of anxiety and depression?
A. Ventral tegmental area (VTA)
B. Raphe nuclei
Page 1
, NR-546 Midterm Exam | Advanced Pharmacology Psychopharmacology for the PMHNP Chamberlain University | 2026-2027
C. Locus coeruleus [CORRECT]
D. Substantia nigra (SN)
Correct Answer: C
Rationale: The locus coeruleus is the primary source of norepinephrine in the brain, containing the cell bodies of
noradrenergic neurons that project widely throughout the cerebral cortex, limbic system, thalamus, and cerebellum.
Dysregulation of the locus coeruleus-NE system is implicated in the pathophysiology of anxiety disorders, depression,
PTSD, and attention-deficit/hyperactivity disorder. Hyperactivity of the locus coeruleus is associated with increased
anxiety and arousal. The VTA and substantia nigra are the primary sources of dopamine, not norepinephrine. The raphe
nuclei are the primary source of serotonin (5-HT). Understanding the locus coeruleus is essential for PMHNPs because
many psychotropic medications, including SNRIs and TCAs, modulate norepinephrine activity.
Q4: A PMHNP is explaining the mechanism of action of atypical antipsychotics to a nursing student.
Atypical antipsychotics like aripiprazole act as partial agonists at which receptor?
A. 5-HT2A receptor
B. D2 (dopamine-2) receptor [CORRECT]
C. 5-HT1A receptor
D. NMDA receptor
Correct Answer: B
Rationale: Aripiprazole is a unique atypical antipsychotic that acts as a partial agonist at the D2 (dopamine-2) receptor.
As a partial agonist, it has intrinsic activity but less than a full agonist; when dopamine levels are high (such as in the
mesolimbic pathway in psychosis), it competes with dopamine and reduces excessive dopaminergic signaling. When
dopamine levels are low (such as in the mesocortical pathway in negative symptoms), it provides some dopaminergic
stimulation, which may improve negative symptoms and reduce extrapyramidal side effects. This functional selectivity
differentiates aripiprazole from typical antipsychotics, which are pure D2 antagonists. While atypical antipsychotics also
block 5-HT2A receptors, the defining pharmacological characteristic of aripiprazole is its partial D2 agonism.
Q5: A patient on long-term lithium therapy develops a fine tremor. The PMHNP recognizes that lithium's
therapeutic mechanism involves modulation of which intracellular signaling pathway?
A. cAMP (cyclic adenosine monophosphate) pathway
B. Inositol phosphate (phosphatidylinositol) pathway [CORRECT]
C. JAK-STAT signaling pathway
D. NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway
Correct Answer: B
Rationale: Lithium's mechanism of action, while not fully elucidated, is known to involve modulation of the inositol
phosphate (phosphatidylinositol) second messenger pathway. Lithium inhibits the enzyme inositol monophosphatase
(IMPase), which is critical for the recycling of inositol in the phosphatidylinositol signaling system. This depletion of free
inositol dampens overactive intracellular signaling that is thought to contribute to the pathophysiology of bipolar disorder.
Lithium also inhibits glycogen synthase kinase-3 (GSK-3), which has neuroprotective effects and upregulates brain-derived
neurotrophic factor (BDNF), supporting neuroplasticity. While lithium does have some effects on the cAMP pathway, its
primary and most well-characterized mechanism involves the inositol depletion hypothesis. The JAK-STAT and NF-kB
pathways are not the primary targets of lithium.
Q6: Which neurotransmitter system is primarily responsible for regulating mood, sleep, appetite, impulse
control, and pain perception?
A. Dopamine
B. Norepinephrine
C. Serotonin (5-hydroxytryptamine, 5-HT) [CORRECT]
Page 2
U NIVE RS ITY
W EEK 4 M IDT ERM EXA M INAT ION
NR-546 Advanced Pharmacology:
Psychopharmacology for the
PMHNP
Course: NR-546 Advanced Pharmacology
Total Questions: 75 Multiple Choice
Academic Year:
Curriculum: Weeks 1 - 4 Comprehensive
100% C or r ect Answer s | Gr ad e A Ver ified
,NR-546 Midterm Exam | Advanced Pharmacology Psychopharmacology for the PMHNP Chamberlain University | 2026-2027
Section 1: Neurobiology and Neurotransmission Fundamentals
(Weeks 1-2)
Q1: A PMHNP student is reviewing synaptic neurotransmission. Which of the following correctly describes
the sequence of events at a chemical synapse?
A. Action potential arrives at the axon terminal, calcium enters the presynaptic terminal,
synaptic vesicles fuse with the presynaptic membrane, neurotransmitter is released into the
synaptic cleft, and binds to postsynaptic receptors [CORRECT]
B. Neurotransmitter is synthesized in the postsynaptic neuron, travels across the synaptic cleft, binds to
presynaptic autoreceptors, and triggers calcium release from intracellular stores
C. Calcium is released from the postsynaptic neuron, vesicles migrate from the postsynaptic
membrane, neurotransmitter diffuses across the cleft, and binds to presynaptic receptors
D. The action potential directly causes neurotransmitter release without calcium involvement, the
neurotransmitter binds to ion channels, and the signal is terminated by enzymatic degradation only
Correct Answer: A
Rationale: The correct sequence of synaptic transmission begins with the arrival of an action potential at the axon
terminal, which opens voltage-gated calcium channels, allowing calcium to enter the presynaptic terminal. This calcium
influx triggers synaptic vesicles containing neurotransmitter to fuse with the presynaptic membrane and release their
contents into the synaptic cleft. The neurotransmitter then diffuses across the cleft and binds to specific receptors on the
postsynaptic membrane. Option B incorrectly describes neurotransmitter synthesis in the postsynaptic neuron and
presynaptic autoreceptor binding as the primary event. Option C reverses the presynaptic and postsynaptic roles. Option D
is incorrect because calcium influx is essential for vesicle fusion and neurotransmitter release, and signal termination
involves reuptake, enzymatic degradation, and diffusion, not degradation alone.
Q2: A patient with major depressive disorder (MDD) is prescribed an SSRI. The PMHNP explains that the
therapeutic effect requires downregulation of which receptor type?
A. 5-HT2A receptors
B. 5-HT1A autoreceptors [CORRECT]
C. 5-HT3 receptors
D. 5-HT2C receptors
Correct Answer: B
Rationale: SSRIs initially block the serotonin transporter (SERT), increasing serotonin in the synaptic cleft. However, the
acute increase in synaptic serotonin also activates presynaptic 5-HT1A autoreceptors, which provide negative feedback and
reduce further serotonin release. Over 2-4 weeks of treatment, these 5-HT1A autoreceptors become desensitized and
downregulated, removing the inhibitory feedback and allowing sustained enhancement of serotonergic neurotransmission.
This delay in autoreceptor downregulation explains the therapeutic lag observed with SSRIs. 5-HT2A receptors are targeted
by antipsychotics and are associated with hallucinogenic effects. 5-HT3 receptors are involved in nausea and are targeted
by antiemetics such as ondansetron. 5-HT2C receptors are primarily associated with appetite regulation.
Q3: Which brain region is the primary source of norepinephrine (NE) and is most relevant to understanding
the pathophysiology of anxiety and depression?
A. Ventral tegmental area (VTA)
B. Raphe nuclei
Page 1
, NR-546 Midterm Exam | Advanced Pharmacology Psychopharmacology for the PMHNP Chamberlain University | 2026-2027
C. Locus coeruleus [CORRECT]
D. Substantia nigra (SN)
Correct Answer: C
Rationale: The locus coeruleus is the primary source of norepinephrine in the brain, containing the cell bodies of
noradrenergic neurons that project widely throughout the cerebral cortex, limbic system, thalamus, and cerebellum.
Dysregulation of the locus coeruleus-NE system is implicated in the pathophysiology of anxiety disorders, depression,
PTSD, and attention-deficit/hyperactivity disorder. Hyperactivity of the locus coeruleus is associated with increased
anxiety and arousal. The VTA and substantia nigra are the primary sources of dopamine, not norepinephrine. The raphe
nuclei are the primary source of serotonin (5-HT). Understanding the locus coeruleus is essential for PMHNPs because
many psychotropic medications, including SNRIs and TCAs, modulate norepinephrine activity.
Q4: A PMHNP is explaining the mechanism of action of atypical antipsychotics to a nursing student.
Atypical antipsychotics like aripiprazole act as partial agonists at which receptor?
A. 5-HT2A receptor
B. D2 (dopamine-2) receptor [CORRECT]
C. 5-HT1A receptor
D. NMDA receptor
Correct Answer: B
Rationale: Aripiprazole is a unique atypical antipsychotic that acts as a partial agonist at the D2 (dopamine-2) receptor.
As a partial agonist, it has intrinsic activity but less than a full agonist; when dopamine levels are high (such as in the
mesolimbic pathway in psychosis), it competes with dopamine and reduces excessive dopaminergic signaling. When
dopamine levels are low (such as in the mesocortical pathway in negative symptoms), it provides some dopaminergic
stimulation, which may improve negative symptoms and reduce extrapyramidal side effects. This functional selectivity
differentiates aripiprazole from typical antipsychotics, which are pure D2 antagonists. While atypical antipsychotics also
block 5-HT2A receptors, the defining pharmacological characteristic of aripiprazole is its partial D2 agonism.
Q5: A patient on long-term lithium therapy develops a fine tremor. The PMHNP recognizes that lithium's
therapeutic mechanism involves modulation of which intracellular signaling pathway?
A. cAMP (cyclic adenosine monophosphate) pathway
B. Inositol phosphate (phosphatidylinositol) pathway [CORRECT]
C. JAK-STAT signaling pathway
D. NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway
Correct Answer: B
Rationale: Lithium's mechanism of action, while not fully elucidated, is known to involve modulation of the inositol
phosphate (phosphatidylinositol) second messenger pathway. Lithium inhibits the enzyme inositol monophosphatase
(IMPase), which is critical for the recycling of inositol in the phosphatidylinositol signaling system. This depletion of free
inositol dampens overactive intracellular signaling that is thought to contribute to the pathophysiology of bipolar disorder.
Lithium also inhibits glycogen synthase kinase-3 (GSK-3), which has neuroprotective effects and upregulates brain-derived
neurotrophic factor (BDNF), supporting neuroplasticity. While lithium does have some effects on the cAMP pathway, its
primary and most well-characterized mechanism involves the inositol depletion hypothesis. The JAK-STAT and NF-kB
pathways are not the primary targets of lithium.
Q6: Which neurotransmitter system is primarily responsible for regulating mood, sleep, appetite, impulse
control, and pain perception?
A. Dopamine
B. Norepinephrine
C. Serotonin (5-hydroxytryptamine, 5-HT) [CORRECT]
Page 2
